Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia

Abstract Background Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide reduces low-density lipoprotein cholesterol (LDL-C) levels; however, the probable impact on LDL-C goals and CV even...

Full description

Bibliographic Details
Main Authors: Dirk J. Blom, Marina Cuchel, Miranda Ager, Helen Phillips
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
(3–10): Homozygous familial hypercholesterolemia
Lomitapide
Number needed to treat
Target
Low-density lipoprotein cholesterol
Major adverse cardiovascular event
Online Access:http://link.springer.com/article/10.1186/s13023-018-0841-3

Internet

http://link.springer.com/article/10.1186/s13023-018-0841-3

Similar Items